Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sheba, Lonza Collaborate on Cell Therapy Mfg. Platform | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sheba, Lonza Collaborate on Cell Therapy Mfg. Platform

Will assess automated CAR-T cell therapy manufacturing at the point-of-care

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sheba Medical Center at Tel Hashomer, and Lonza have entered a collaboration to develop point-of-care cell-therapy manufacturing using the Cocoon manufacturing platform. The partnership will enable Sheba to streamline its in-house cell manufacturing process and produce genetically engineered human CAR-T cells for applications in treating critically ill oncology patients.
 
This collaborative agreement brings together a leading academic clinical center and an established development and manufacturing partner with the goal of delivering potentially curative therapies to a greater number of patients with advanced hematological malignancies. Sheba Medical Center treats oncology patients using novel immunotherapy treatments such as CAR-T, and Lonza will leverage its expertise in autologous cell-therapy process development to transfer Sheba’s current open, manual protocols into Lonza’s closed, automated Cocoon platform.
  
Eytan Abraham, head of Personalized Medicine, Lonza Pharma Biotech & Nutrition said, “This collaboration with Sheba Medical Center, a proven leader in point-of-care manufacturing and treatment of patients with novel immunotherapies, is a key part of the development program for the CocoonTM platform. We aim to confirm the benefits of using our closed, automated GMP-in-a-box concept to more efficiently manufacture personalized cell therapies right where the patients are, enabling treatment of a larger patient population.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters